Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting Alector's scientific approach, the Company's Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, to improve the probability of technical success over short development timelines. As a result, in the last five years, the Company has identified over forty immune system targets, progressed over ten programs into preclinical research, and advanced two product candidates, AL001 and AL002, into clinical development. In the second half of 2018, the Company also initiated a dose escalation Phase 1 study in healthy volunteers with AL002, a product candidate for Alzheimer's disease. Alector expects to initiate Phase 1 studies of AL003, a product candidate for Alzheimer's disease, and AL101, a product candidate for multiple neurodegenerative disorders, in 2019